Amarin Corporation PLCNASDAQ:AMRNNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.5063
- TODAY'S CHANGE (%)-0.0227 (-4.2911%)
- Bid / Lots0.5050/ 2
- Ask / Lots0.5076/ 18
- Open / Previous Close0.5200 / 0.5290
- Day Range
- 52 Week Range
- Volume1,367,420
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AMRN |
|---|---|---|
| 09:32 ET | 47566 | 0.51 |
| 09:33 ET | 7200 | 0.5151 |
| 09:35 ET | 1100 | 0.514 |
| 09:37 ET | 390 | 0.5139 |
| 09:39 ET | 8729 | 0.51145 |
| 09:42 ET | 33100 | 0.508486 |
| 09:44 ET | 12700 | 0.5169 |
| 09:46 ET | 22181 | 0.502501 |
| 09:48 ET | 10100 | 0.504401 |
| 09:50 ET | 30600 | 0.5056 |
| 09:51 ET | 16620 | 0.5064 |
| 09:53 ET | 2600 | 0.5132 |
| 09:55 ET | 1100 | 0.51165 |
| 09:57 ET | 13530 | 0.5047 |
| 10:00 ET | 8200 | 0.5132 |
| 10:02 ET | 4895 | 0.5099 |
| 10:04 ET | 428 | 0.5025 |
| 10:06 ET | 4300 | 0.508 |
| 10:08 ET | 29295 | 0.5092 |
| 10:09 ET | 608 | 0.5056 |
| 10:11 ET | 10800 | 0.505601 |
| 10:13 ET | 1000 | 0.506 |
| 10:15 ET | 546 | 0.50608 |
| 10:18 ET | 12897 | 0.5054 |
| 10:20 ET | 6600 | 0.5025 |
| 10:22 ET | 10587 | 0.502 |
| 10:24 ET | 118 | 0.5038 |
| 10:27 ET | 3647 | 0.5021 |
| 10:29 ET | 3251 | 0.5035 |
| 10:31 ET | 285342 | 0.496 |
| 10:33 ET | 500 | 0.5 |
| 10:36 ET | 16500 | 0.4993 |
| 10:38 ET | 5152 | 0.49511 |
| 10:42 ET | 2600 | 0.5017 |
| 10:44 ET | 15384 | 0.501101 |
| 10:45 ET | 25633 | 0.50335 |
| 10:58 ET | 2500 | 0.506339 |
| 11:00 ET | 9453 | 0.5092 |
| 11:02 ET | 5811 | 0.5072 |
| 11:12 ET | 24859 | 0.5109 |
| 11:14 ET | 729 | 0.5076 |
| 11:18 ET | 951 | 0.5081 |
| 11:20 ET | 325 | 0.50845 |
| 11:21 ET | 1086 | 0.51 |
| 11:23 ET | 553 | 0.51 |
| 11:25 ET | 6637 | 0.5086 |
| 11:27 ET | 20666 | 0.51 |
| 11:30 ET | 497 | 0.5093 |
| 11:34 ET | 459 | 0.5093 |
| 11:36 ET | 121973 | 0.5107 |
| 11:38 ET | 734 | 0.5107 |
| 11:39 ET | 39677 | 0.511501 |
| 11:41 ET | 47732 | 0.513 |
| 11:43 ET | 52092 | 0.515642 |
| 11:45 ET | 46823 | 0.5159 |
| 11:48 ET | 24829 | 0.51 |
| 11:54 ET | 800 | 0.51005 |
| 11:56 ET | 2484 | 0.51 |
| 11:57 ET | 500 | 0.51 |
| 12:01 ET | 506 | 0.5073 |
| 12:03 ET | 532 | 0.5086 |
| 12:06 ET | 250 | 0.5071 |
| 12:08 ET | 12100 | 0.5078 |
| 12:10 ET | 3050 | 0.508451 |
| 12:12 ET | 5707 | 0.5067 |
| 12:14 ET | 479 | 0.5077 |
| 12:15 ET | 457 | 0.5077 |
| 12:19 ET | 31161 | 0.5063 |
Nov 11, 2024
Investigators to Present New REDUCE-IT Subanalysis of VASCEPA(R)/VAZKEPA(R) (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association's (AHA) Annual Scientific Sessions, from 8:00AM ET on Monday Nov 11, 2024 by Dow Jones
8:00AM ET on Monday Nov 11, 2024 by Dow Jones
Oct 30, 2024
Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update, from 4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones
4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones*DJ Amarin 3Q Loss/Shr 6c >AMRN, from 4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones
4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Amarin Corporation PLC | 225.7M | -5.3x | --- |
Coherus BioSciences Inc | 125.6M | -14.9x | --- |
Voyager Therapeutics Inc | 308.9M | 9.6x | --- |
Ginkgo Bioworks Holdings Inc | 391.2M | -0.6x | --- |
Amylyx Pharmaceuticals Inc | 361.2M | -1.4x | --- |
Revance Therapeutics Inc | 391.3M | -2.2x | --- |
Company Information
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Contact Information
- Headquarters
- Gemini House, Bartholomews WalkDUBLIN, Ireland FK7 9JQ
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Director
- Odysseas Kostas
- President, Chief Executive Officer, Director
- Aaron Berg
- President - Research and Development, Executive Vice President, Chief Scientific Officer
- Stephen Ketchum
- Executive Vice President, Chief Legal and Compliance Officer, Secretary
- Jonathan Provoost
- Non-Executive Independent Director
- Patrice Bonfiglio
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $225.7M |
|---|---|
Revenue (TTM) | $241.0M |
Shares Outstanding | 411.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.86 |
EPS | $-0.10 |
Book Value | $1.35 |
P/E Ratio | -5.3x |
Price/Sales (TTM) | 0.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -18.30% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
